| Entity | Document Type | Tax ID |
|---|---|---|
| The Breast Cancer Research Foundation | IRS Form 990 | 13-3727250 |
| The Breast Cancer Research Foundation | Consolidated Audited Financial Statements | Multiple |
|
Entity: The Breast Cancer Research Foundation Document Type: IRS Form 990 Tax ID: 13-3727250 |
|
Entity: The Breast Cancer Research Foundation Document Type: Consolidated Audited Financial Statements Tax ID: Multiple |
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Myra Biblowit | President | $779,883 |
| 2 | Marc Hurlbert | Chief Mission Officer | $362,252 |
| 3 | Lucretia Gilbert | Chief Development Officer | $312,982 |
|
1 Name: Myra Biblowit Title: President Compensation: $779,883 |
|
2 Name: Marc Hurlbert Title: Chief Mission Officer Compensation: $362,252 |
|
3 Name: Lucretia Gilbert Title: Chief Development Officer Compensation: $312,982 |
| CharityWatch's rating of Breast Cancer Research Foundation (BCRF) also includes the financial activities of The Breast Cancer Research Foundation in Canada, which are consolidated in BCRF's audited financial statements for the fiscal year ended June 30, 2018. According to the BCRF fiscal 2018 consolidated audit (Note A[1], The Foundation): "As BCRF Canada's assets and liabilities and its operations are not significant, they are not shown separately in the consolidated financial statements. ... All significant inter-organization balances and transactions have been eliminated in [the audit] consolidation." |
| According to The Breast Cancer Research Foundation (BCRF) consolidated audit of June 30, 2018 (Note G, Donated Goods and Services), BCRF received donated goods and services in fiscal 2018 on which it placed a total value of $1,420,000, including $919,000 in donated legal services. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
| According to The Breast Cancer Research Foundation consolidated audit of June 30, 2018 (Note I, Related-Party Transactions): [1] Fundraising: "One member of the Foundation's Board of Directors is also a member of the Board of Directors of a corporation that donated a portion of its sales revenue to the Foundation and held various fund-raising events for the benefit of the Foundation. For fiscal-years 2018 and 2017, the Foundation recognized contribution revenue from the corporation of approximately $7,580,000 and $5,565,000 respectively..." [2] Operating expenses: "The Foundation also reimburses this corporation to cover certain operating expenses paid on its behalf each fiscal-year. These reimbursements to the corporation are for payroll and related benefits for the staff who exclusively conduct the Foundation's activities, as well as reimbursement for other administrative services provided at cost. For fiscal-years 2018 and 2017, these reimbursements approximated $7,502,000 and $6,821,000, respectively..." |
| According to The Breast Cancer Research Foundation consolidated audit of June 30, 2018 (Note J[3], Commitments, Employment agreement): "The Foundation is obligated under an employment agreement with its president. The agreement is automatically extended on an annual basis, unless either party provides 90 days of prior written notice of its intention not to do so." |
| According to The Breast Cancer Research Foundation (BCRF) tax filing for the fiscal year ended June 30, 2018, BCRF reports re: Compensation, Supplemental Information (IRS Form 990, Schedule J, Part III): Regarding nonfixed payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 7): "The Foundation's board of directors authorized a bonus for the president of the Foundation." BCRF reports $30,000 in "Bonus & incentive compensation" paid to its president, Myra Biblowit, in calendar year 2017 as part of her total compensation of $779,883 (IRS Form 990, Schedule J, Part II). |
